Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Concomitant use of venetoclax 100 mg and ketoconazole, a strong CYP3A4 inhibitor, is clinically equivalent to venetoclax 400 mg for treating relapsed or refractory chronic lymphocytic leukemia (CLL): A real-world analysis from the brazilian CLL registry.“

Gabriel Cunha, Pedro Perez, Fernanda Marques, Verena Pfister, Rodrigo Santucci, Milton Aranha, Danielle De Farias, Talita Silveira, Jayr Schmidt Filho, Valeria Buccheri, Roberto Silva, Leila Perobelli, Glaciano Ribeiro, Maura Colturato, Nelson Hamerschlak, Pedro Fernandes, Fernanda Santos Azevedo, Carlos Chiattone, Celso Arrais-Rodrigues

Blood (2025) 146 (Supplement 1): 3909.

https://doi.org/10.1182/blood-2025-3909

Published: 2025

Journal Articles

Baseline clinical characteristics of patients with chronic lymphocytic leukemia (CLL) from 11 Latin American countries: A real-world registry analysis

Ana Oliver, Celso Arrais-Rodrigues, Luis Mario Villela Martinez, Macarena Roa, Sofía Rivarola, Lorena Cardozo, Marialejandra Torres Viera, Denisse Castro, Fabiola Valvert, Daniela Trujillo Loaiza, Anelys García Salgado, Victoria Irigoin, Leila Perobelli, Silvana Cigliari, Alana von Glasenapp, Camila Peña, Sally Paredes, Valeria Buccheri, Virginia Lema Spinelli, Augusto Mirolli, Jose Alvarez, Maura Colturato, Ana Ines Landoni, Gislaine Duarte, Marta Zerga, Sabrina ranero Ferrari, Miguel Pavlovsky, Nancy Cristaldo, Laura Fogliatto, Maria Del Rosario Custidiano, Danielle De Farias, Maria Orlova, Fernando Barroso Duarte, Etelvina Macchiavello, Julio Pose Cabarcos, Sérgio Fortier, Julia Laviano, Clarisa Pagano Vilar, Nelson Hamerschlak, Vera Figueiredo, Fernando Pérez-Jacobo, Javier Retamales, Arianna Robles, German Stemmelin, Rosa Rios Jimenez, Henry Quintero, Brady Beltran, Jorge Castillo, Carlos Chiattone, Luis Malpica

Blood (2025) 146 (Supplement 1): 3908.

https://doi.org/10.1182/blood-2025-3908

Published: 2025

Journal Articles

Frontline therapy patterns and outcomes in chronic lymphocytic leukemia: A real-world, multicenter analysis from Latin America.

Celso Arrais-Rodrigues, Ana Oliver, Maria Cugliari, Luis Mario Villela Martinez, Macarena Roa, Lorena Cardozo, Marialejandra Torres Viera, Denisse Castro, Daniela Trujillo Loaiza, Leila Perobelli, Anelys García Salgado, Victoria Irigoin, Sofía Rivarola, Virginia Lema Spinelli, Jose Alvarez, Alana von Glasenapp, Camila Peña, Sally Paredes, Valeria Buccheri, Gislaine Duarte, Maura Colturato, Laura Fogliatto, Ana Ines Landoni, Sabrina ranero Ferrari, Augusto Mirolli, Marta Zerga, Miguel Pavlovsky, Nancy Cristaldo, Maria Del Rosario Custidiano, Fernando Pérez-Jacobo, Danielle De Farias, Maria Orlova, Julio Pose Cabarcos, Fernando Barroso Duarte, Etelvina Macchiavello, Sérgio Fortier, Julia Laviano, Clarisa Pagano Vilar, Nelson Hamerschlak, Vera Figueiredo, Rosa Rios Jimenez, Arianna Robles, Javier Retamales, Melanie Otañez, German Stemmelin, Henry Idrobo, Brady Beltran, Jorge Castillo, Luis Malpica, Carlos Chiattone

Blood (2025) 146 (Supplement 1): 2775.

https://doi.org/10.1182/blood-2025-2775

Published: 2025

Journal Articles

First-line venetoclax-based regimens versus chemoimmunotherapy in chronic lymphocytic leukemia: A real-world analysis from the brazilian CLL registry

Samir Nabhan, Gabriel Cunha, Verena Pfister, Leila Perobelli, Erika Oshiro, Rodrigo Santucci, Milton Aranha, Talita Silveira, Jayr Schmidt Filho, Danielle De Farias, Cristiana Solza, Valeria Buccheri, Thiago Carneiro, Vera Figueiredo, Maura Colturato, Abel Costa, Fernanda Marques, Caio Cesar Justino, Celso Arrais-Rodrigues

Blood (2025) 146 (Supplement 1): 7413.

https://doi.org/10.1182/blood-2025-7413

Published: 2025

Journal Articles

Real-world treatment patterns and outcomes in patients with CLL and cardiovascular comorbidities: Interim analysis of the multicenter study conducted by eric.

Thomas Chatzikonstantinou, Sevasti Konstantinou, Persefoni Talimtzi, Eva Minga, Maria Angelopoulou, Francesco Angotzi, Marcello Bradaschia, Sophia Chatzileontiadou, Caterina Chessa, Marta Crespo, Maria Dimou, Alessandro Gozzetti, Ritu Gupta, Eliana Konstantinou, Andreas Epameinondas Koumpis, Alexandros Machairas, Francesca Martini, Riccardo Moia, Samir Mouhssine, Roberta Murru, Leila Perobelli, Lata Rani, Ilaria Romano, Gian Matteo Rigolin, Angel Serna, Andrea Visentin, Candida Vitale, George Vrachiolias, Celso Arrais-Rodrigues, Rodrigo Santucci da Silva, Carlos Chiattone, Francesc Bosch Albareda, Anastasia Chatzidimitriou, Marta Coscia, Antonio Cuneo, Gianluca Gaidano, Eleftheria Hatzimichael, Yair Herishanu, Ioannis Kotsianidis, Panagiotis Panagiotidis, Maria Papaioannou, Davide Rossi, Niki Stavrogianni, Livio Trentin, Theodoros Vassilakopoulos, Kostas Stamatopoulos, Paolo Ghia, Lydia Scarfo

Blood (2025) 146 (Supplement 1): 5665.

https://doi.org/10.1182/blood-2025-5665

Published: 2025

Journal Articles

Survival differences of patients with treatment-naive CLL between the chemoimmunotherapy and BTKi eras: An eric study.

Thomas Chatzikonstantinou, Persefoni Talimtzi, Eva Minga, Maria Angelopoulou, Miguel Arguello De Tomas, Darko Antic, Celso Arrais-Rodrigues, Francesc Bosch Albareda, Marcello Bradaschia, Alessandro Cellini, Mark Catherwood, Sophia Chatzileontiadou, Caterina Chessa, Carlos Chiattone, Rosa Collado, Marta Coscia, Marta Crespo, Antonio Cuneo, Zadie Davis, Maria Dimou, Michael Doubek, Maria Efstathopoulou, Blanca Espinet, Gianluca Gaidano, Rocio Garcia-Serra, Alessandro Gozzetti, Ritu Gupta, Eleftheria Hatzimichael, Yair Herishanu, Ozren Jaksic, Maria Kislova, Eliana Konstantinou, Sevasti Konstantinou, Maya Koren Michowitz, Ioannis Kotsianidis, Andreas Epameinondas Koumpis, Luca Laurenti, Alexandros Machairas, Francesca Martini, Riccardo Moia, Samir Mouhssine, Ana Muntanola Prat, Roberta Murru, Rocio Nieves Salgado Sanchez, Gerassimos Pangalis, Maria Papaioannou, Sarka Pavlova, Leila Perobelli, Sarka Pospisilova, Anna Puiggros, Claus Rainer, Sergio Ramos, Lata Rani, Gian Matteo Rigolin, Ilaria Romano, Davide Rossi, Rodrigo Santucci, Angel Serna, Marina Siakantaris, Talita Silveira, Paolo Sportoletti, Niki Stavrogianni, Annamaria Tomasso, Kristina Tomic Vujovic, Livio Trentin, Theodoros Vassilakopoulos, Andrea Visentin, Candida Vitale, George Vrachiolias, Munci Yagci, Seyma Yildiz, Anastasia Chatzidimitriou, Kostas Stamatopoulos, Paolo Ghia, Lydia Scarfo

Blood (2025) 146 (Supplement 1): 5664.

https://doi.org/10.1182/blood-2025-5664

Published: 2025

Journal Articles

Real-World Analysis of Patients with CLL Treated with Ibrutinib: A Retrospective Analysis of the Brazilian Registry of CLL

Verena Pfister, Fernanda de Morais Marques, Vinicius Campos de Molla, Flavia Parra, Mihoko Yamamoto, Rodrigo Santucci, Milton A. F. Aranha, Valeria Buccheri, Glaciano Ribeiro, Vera Figueiredo, Nelson Hamerschlak, Abel Costa Neto, Jayr Schmidt Filho, Talita Silveira, Adriana Scheliga, Matheus Vescovi Goncalves, Leila Perobelli, Carlos Chiattone, Celso Arrais-Rodrigues

Blood (2024) 144 (Supplement 1): 2348.

https://doi.org/10.1182/blood-2024-210706

Published: 2024

Journal Articles

Smoldering Multiple Myeloma in Latin America- Risk Stratification

Blood (2024) 144 (Supplement 1): 3774.

https://doi.org/10.1182/blood-2024-209038

Published: 2024

Journal Articles

Outcomes of Conservative Indication Criteria for First-Line Treatment in Chronic Lymphocytic Leukemia: Insights from the Brazilian Registry of CLL

Blood (2023) 142 (Supplement 1): 6534.

https://doi.org/10.1182/blood-2023-190590

Published: 2023

Journal Articles

External Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI): Strong Calibration in the Brazilian Prospective Hodgkin Lymphoma Registry

Blood (2023) 142 (Supplement 1): 6200.

https://doi.org/10.1182/blood-2023-173318

Published: 2023

Journal Articles

Real World Evidence- the Proportion of Myeloma Patients' Death Due to Early Progression

Blood (2023) 142 (Supplement 1): 3789.

https://doi.org/10.1182/blood-2023-187790

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Concomitant use of venetoclax 100 mg and ketoconazole, a strong CYP3A4 inhibitor, is clinically equivalent to venetoclax 400 mg for treating relapsed or refractory chronic lymphocytic leukemia (CLL): A real-world analysis from the brazilian CLL registry.“

Baseline clinical characteristics of patients with chronic lymphocytic leukemia (CLL) from 11 Latin American countries: A real-world registry analysis

Frontline therapy patterns and outcomes in chronic lymphocytic leukemia: A real-world, multicenter analysis from Latin America.

First-line venetoclax-based regimens versus chemoimmunotherapy in chronic lymphocytic leukemia: A real-world analysis from the brazilian CLL registry

Real-world treatment patterns and outcomes in patients with CLL and cardiovascular comorbidities: Interim analysis of the multicenter study conducted by eric.

Survival differences of patients with treatment-naive CLL between the chemoimmunotherapy and BTKi eras: An eric study.

Real-World Analysis of Patients with CLL Treated with Ibrutinib: A Retrospective Analysis of the Brazilian Registry of CLL

Smoldering Multiple Myeloma in Latin America- Risk Stratification

Outcomes of Conservative Indication Criteria for First-Line Treatment in Chronic Lymphocytic Leukemia: Insights from the Brazilian Registry of CLL

External Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI): Strong Calibration in the Brazilian Prospective Hodgkin Lymphoma Registry

Real World Evidence- the Proportion of Myeloma Patients' Death Due to Early Progression

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only